Praxis Precision Medicines Retained Earnings (Accumulated Deficit) 2019-2024 | PRAX

Praxis Precision Medicines retained earnings (accumulated deficit) from 2019 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.

Praxis Precision Medicines Retained Earnings (Accumulated Deficit) 2019-2024 | PRAX

Praxis Precision Medicines retained earnings (accumulated deficit) from 2019 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$174.8B
Vertex Pharmaceuticals (VRTX)$133.1B
Gilead Sciences (GILD)$120.2B
Bristol Myers Squibb (BMY)$109.8B
Regeneron Pharmaceuticals (REGN)$91B
CSL (CSLLY)$90.5B
GSK (GSK)$75.2B
Alnylam Pharmaceuticals (ALNY)$35.8B
Argenex SE (ARGX)$35.6B
BioNTech SE (BNTX)$26.3B
Biogen (BIIB)$25.2B
Illumina (ILMN)$24B
BeiGene (BGNE)$20B
Moderna (MRNA)$18B
Incyte (INCY)$16.1B
Genmab (GMAB)$15.3B
Vaxcyte (PCVX)$13.3B
Insmed (INSM)$13.2B
BioMarin Pharmaceutical (BMRN)$12.8B
Bio-Techne Corp (TECH)$12.1B
Sarepta Therapeutics (SRPT)$11.6B
Exelixis (EXEL)$10.4B
Revolution Medicines (RVMD)$10.2B
QIAGEN (QGEN)$10B
Intra-Cellular Therapies (ITCI)$9.7B
Exact Sciences (EXAS)$9.5B
Bio-Rad Laboratories (BIO.B)$9.4B
Roivant Sciences (ROIV)$8.8B
Repligen (RGEN)$7.9B
Halozyme Therapeutics (HALO)$7.8B